Critical limb ischemia: cell and molecular therapies for limb salvage.
There is a growing interest in developing new limb salvage therapies for patients with severe peripheral artery disease who have no alternative to amputation. Cell and gene therapy studies are showing promise in controlling pain and minor ulceration in patients with significant critical limb ischemia. Among cardiovascular cell and molecular therapy programs, The Methodist Hospital is one of the leading centers in both gene and cell therapy for critical limb ischemia. Randomized controlled trials continue to be performed, and these experimental therapies will move from research to pharmacy within the decade. In conjunction with aggressive medical and surgical management, these emergent therapies may help patients with critical limb ischemia avoid a major amputation and are one of the foundations of any advanced limb salvage program.
Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, Texas, USA.
Mark G
MG
Davies
D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D006801:Humans; D007511:Ischemia / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D023821:Limb Salvage; D058990:Molecular Targeted Therapy / Q000379:methods*
amputation; arteriogenesis; cell therapy; critical limb ischemia; fibroblast growth factor (FGF); gene therapy; hepatocyte growth factor (HGF); limb salvage; molecular therapy; therapeutic angiogenesis; vascular endothelial cell growth factor (VEGF); vasculogenesis